Pharmacogenetics: from bench to byte--an update of guidelines
| Autor: | Henk-Jan Guchelaar, Tom Schalekamp, A. de Boer, V.H.M. Deneer, Bob Wilffert, L. Grandia, J. van der Weide, Jesse J. Swen, A.H. Maitland-van der Zee, Marga Nijenhuis, Hans Mulder, Gerard A. Rongen, R.H.N. van Schaik, Daan J Touw |
|---|---|
| Přispěvatelé: | Nanomedicine & Drug Targeting, Methods in Medicines evaluation & Outcomes research (M2O), Reproductive Origins of Adult Health and Disease (ROAHD), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Groningen Research Institute for Asthma and COPD (GRIAC), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Medicinal Chemistry and Bioanalysis (MCB), General Practice, Cardiology, Clinical Chemistry |
| Rok vydání: | 2011 |
| Předmět: |
Oncology
vomiting loading drug dose HLA B gene genotype phenotype correlation glucuronosyltransferase 1A1 zuclopenthixol thiopurine methyltransferase Pharmacology nortriptyline Phenprocoumon esomeprazole venlafaxine Pharmacology (medical) citalopram TPMT gene propafenone glimepiride HLA B44 gene pharmacogenetics Cardiovascular diseases [NCEBP 14] tamoxifen gene product phenytoin article nausea unclassified drug imipramine CYP2C9 gene confusion Pharmaceutical Preparations priority journal sedation glibenclamide Practice Guidelines as Topic Vitamin K epoxide reductase Aryl Hydrocarbon Hydroxylases VKORC1 medicine.drug paroxetine nystagmus tramadol drug dose increase medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions side effect escitalopram respiration depression olanzapine pantoprazole Pharmacy CYP2C19 gliclazide oxycodone Drug Administration Schedule moclobemide CYP3A5 gene urine retention vitamin K epoxide reductase CYP2C19 gene dysarthria Internal medicine medicine Dihydropyrimidine dehydrogenase Factor V Leiden unindexed drug Animals Humans human drug dose reduction gene Cytochrome P-450 CYP2C9 clopidogrel risperidone business.industry dihydropyrimidine dehydrogenase drug dose titration ataxia recommended drug dose constipation medicine.disease blood clotting factor 5 Leiden tolbutamide phenprocoumon CYP2D6 gene DPD gene VKORC1 gene business FVL gene Pharmacogenetics |
| Zdroj: | Clinical Pharmacology & Therapeutics, 89(5), 662-673. Nature Publishing Group Clinical Pharmacology & Therapeutics, 89(5), 662-673. Wiley-Blackwell Clinical Pharmacology and Therapeutics, 89, 662-73 Clinical Pharmacology and Therapeutics, 89, 5, pp. 662-73 |
| ISSN: | 0009-9236 |
| Popis: | Item does not contain fulltext Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text